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METHOD AND APPARATUS FOR THE COLLECTION,
STORAGE, AND REAL TIME ANALYSIS OF BLOOD
AND OTHER BODILY FLUIDS
One of the primary means used to diagnose the state of a person's health is to analyze the person's
blood or other bodily fluids for the presence or absence of analytes indicative of the person's
health. Analytes such as hormones, salts, enzymes, ketones, glucose, drugs, infectious agents,
etc., indicate whether the person has contracted an infection and/or whether the person's glands
and/or other organs are functioning effectively. In order to obtain the most accurate analysis of
the blood, it is important to separate the analytes from the cellular fraction of the blood relatively
quickly after the sample is drawn to avoid altering of the analysis by the cellular fraction. Also,
the manner in which the cellular fraction is separated from the acellular fraction of the blood is
important in order to avoid contamination of the acellular fraction with components from the
cellular fraction.
The invention provides a simple, portable, relatively inexpensive apparatus for accurately and
efficiently collecting, separating, testing, and storing between 1-20 ml of blood or other bodily
fluid in situ. The apparatus includes a collection chamber bounded on its sides by an opening in a
sheet of material, preferably clear plastic, abutting a filter card. The filter card is made of fibrous
material, preferably less than about a millimeter thick, having an average pore size of less than
about 3 microns. Preferably, the fibers are glass and the fibrous material has an average pore size
of about 1 micron. The fibrous material is treated with a carbohydrate/protein mixture which
contains between about 1-40% weight/volume carbohydrate and about 0.1-15% weight/volume
nonspecific protein. A preferred carbohydrate/protein mixture comprises about 10% mannitol and
about 6% albumin. The blood or other fluid moves through the filter card by capillary action
aided by an absorbent matrix with a high Klemm factor which abuts the filter card. The absorbent
matrix and/or filter card can be treated with a wide spectrum of test reagents. The speed,
cleanliness, and efficiency of the separation process can be altered by: (a) changing the absolute
concentration of the carbohydrate/protein mixture; Co) applying positive or negative pressure to
one side of the filter; and/or (c) varying the relative density and pore size of the filter card and
absorbent matrix.
Novelty is believed to exist in an accurate, efficient process for in situ collection, separation,
testing, and storage of bodily fluids, such as blood, which can be used for a broad spectrum of
analytes.
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METHOD AND APPARATUS FOR THE COLLECTION,
STORAGE, AND REAL TIME ANALYSIS OF BLOOD AND
OTHER BODILY FLUIDS
Qriqin Qf the Invention
5 The invention described herein was made in the
performance of work under a NASA contract and is subject to
the provisions of Section 305 of the National Aeronautics and
Space Act of 1958, Public Law 85-568 (72 Star. 435; 42 U.S.C.
2457).
i0 Field of the Invention
The present invention provides a simple, inexpensive
method and apparatus for passively separating cellular (or
solid) and acellular fractions of clinically useful volumes of
bodily fluids, for substantially simultaneously or
15 subsequently analyzing said bodily fluids for one or more
analytes, and for prolonged preservation of said analytes.
BackQround of the Invention
One of the primary means used to diagnose the state of a
person's health is to analyze the person's blood or other
20 bodily fluids for the presence or absence of "analytes"
indicative of the person's health. An "analyte" is any
substance contained in a bodily fluid for which either
knowledge of the presence or concentration is desired for
clinical or laboratory purposes, or for which the substance
1
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itself is retained and used for some other analytical or
pharmacological purpose. Analytes such as hormones, salts,
enzymes, ketones, glucose, drugs, infectious agents, etc.,
indicate whether the person has contracted an infection and/or
5 whether the person's glands and/or other organs are
functioning effectively.
Certain bodily fluids, such as urine, saliva, semen, etc.
can be obtained non-invasively, and analysis of such fluids
can provide information about the state of a person's health.
i0 Some analytes will be found only in certain bodily fluids,
such as cerebrospinal fluid. However, the bodily fluid that
typically gives the most complete picture of a person's health
is whole blood.
One difficulty encountered in analyzing many bodily
15 fluids, such as whole blood, is that the "fluid" actually is
composed of both solid and liquid components. For example,
whole blood is composed of two fractions. One fraction is a
"cellular" fraction, which includes the various types of blood
cells and any other relatively "solid" matter found in the
20 blood. The other fraction is an "acellular" fraction which
consists of plasma or serum. Most of the "analytes" of
interest are contained in the acellular fraction.
In order to obtain the most accurate analysis of the
blood, it is important to separate the analytes from the
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cellular fraction of the blood relatively quickly after the
sample is drawn. Otherwise, the quantity and or quality of
various analytes in the blood may be altered by the cellular
fraction, e.g., by metabolism, release of intracellular
5 content, and/or simple dilution.
For similar reasons, the manner in which the cellular
fraction is separated from the acellular fraction of the blood
is important in order to avoid contamination of the acellular
fraction with components from the cellular fraction. For
I0 example, the separation process, itself, can cause the cells
in the sample to lyse and release the intercellular content
into the sample, thereby contaminating the sample.
Methods for separating clinically useful volumes of blood
generally require the blood to be collected, transferred into
15 a glass or plastic vial, and then centrifuged at high speed
for a period of time. Centrifugation causes the cellular or
solid fraction of the sample to collect at the bottom of the
vial and the acellular supernatant plasma or serum to collect
at the top of the vial. The supernatant then can be decanted
20 and analyzed.
density inert
substantially
fraction when centrifuged,
frozen and stored together.
Sometimes, the vial is provided with a medium
gel which--due to its specific gravity--
isolates the cellular from the acellular
permitting the components to be
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Centrifugation and subsequent refrigeration of samples is
sufficient to preserve the integrity of a sample of blood or
other bodily fluid for a sufficient period of time in most
cases. However, the process is cumbersome and expensive
5 because it requires the blood or other sample either to be
collected in a location having all of the proper equipment, or
that the sample be refrigerated and transferred to a separate
laboratory for further processing. Also, a substantial amount
of time is required to obtain the results of the analysis.
i0 Time may be critical to the life or health of the patient;
therefore, a more rapid, less expensive, less cumbersome
method is needed to analyze samples of blood and/or other
bodily fluids.
Some methods exist for separating and analyzing very
15 small volumes of blood or other bodily fluids in situ.
Typically, these methods involve exposing the blood or other
sample to a porous membrane or a porous mat of glass, fiber,
or a polymer of plastic, protein, or carbohydrate, which traps
the cellular components (or solids) but permits the plasma to
20 flow through onto a paper or plastic strip where the plasma is
reacted immediately with analytical reagents.
Unfortunately, current methods and devices used for in
situ analyses produce only a very small volume of serum or
plasma which can be used only to measure one or a limited
MSC-22463-I Patent Application
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number of small analytes, such as glucose, electrolytes, and
pH. The sample of blood must be small--typically less than
i00 microliters. Because the entire sample is reacted
immediately with the testing reagent(s), the entire sample is
5 disposed of after it has been used for this limited purpose.
None of the sample can be stored or used for any other
testing.
The in situ separation devices in current use often
either do not separate the sample into cellular and acellular
i0 fractions, or they separate the serum into subfractions,
thereby altering the biochemistry of the serum. Also, the
type of analyses that can be performed using such devices
typically is a one stage procedure. The analyte is mixed with
one or a number of reagents simultaneously to produce a color
15 change or chemical reaction. Because these devices lack a
supportive matrix and a path through which the sample can pass
before further analysis, they cannot be used to perform a
multiple stage analysis capable of measuring complex
molecules, such as hormones, enzymes, antibodies, or viral
20 particles. In addition, the accuracy of such analyses is
impaired by the presence of hemoglobin, which is freed by the
hemolysis or rupture of red blood cells in the sample.
The current methods used to test bodily fluids in situ
also lack a convenient means for prolonged storage of viable
5
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samples. Currently, samples of
refrigerated at or below -20°C in
biochemical integrity of the sample.
tested for certain short lived
bodily fluids must be
order to maintain the
If the sample is to be
or delicate analytes,
5 preservatives and/or acids often must be added to preserve the
integrity of the analytes.
Some tests permit whole blood samples to be stored on
blotting paper dried in air--for example, for neonatal
purposes. However, these dried samples: can be used only to
i0 test qualitatively for a limited number of analytes; cannot be
used for quantitative testing; and, only remain viable for
testing for about two weeks. The short term viability for
such dried samples largely results because the blood cells
tend to rupture and contaminate the sample with intracellular
15 contents during the drying process. The free hemoglobin
released in the rehydration process also interferes with many
colorimetric assays.
Some analytes, such as insulin, can be preserved in a
desiccated state by freeze drying the analyte under a vacuum.
20 Unfortunately, a significant number of analytes that can be
preserved in a desiccated state denature at some point during
the process. Therefore, freeze drying of analytes is only of
limited use to test for analytes that do not denature.
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An accurate, efficient process for in situ collection,
separation, testing, and storage of bodily fluids, such as
blood, which can be used for a broad spectrum of analytes
would be highly desirable.
5 SQMMARY QF THE INVENTIQN
The present invention provides a simple, portable,
relatively inexpensive apparatus for accurately and
efficiently collecting, separating, testing, and even storing
between about 1-20 ml, preferably between about i-i0 ml, of
i0 blood or other bodily fluid in situ. The apparatus includes
a collection chamber bounded on its sides by an opening in a
sheet of material, preferably clear plastic, abutting a filter
card. The filter card is made of fibrous material, preferably
glass fiber material less than about a millimeter thick,
15 having an average pore size of less than about 3 microns, more
preferably less than about 1 micron. The fibrous material is
treated with a carbohydrate/protein mixture which contains
between about 1-40% wt/vol carbohydrate and about 0.1-15%
wt/vol non-specific protein, preferably between about 10-20%
20 carbohydrate and about 5-8% protein. A preferred
carbohydrate/protein mixture comprises about 10% mannitol and
about 6% albumin. The blood or other fluid moves through the
filter card by capillary action aided by an absorbent matrix
that has a high Klemm factor which abuts the filter card. The
7
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absorbent matrix and/or filter card can be treated with a wide
spectrum of test reagents. The speed, cleanliness, and
efficiency of the separation process can be altered by: (a)
changing the absolute concentration of the
5 carbohydrate/protein mixture; (b) applying positive or
negative pressure to one side of the filter; and/or (c)
varying the relative density and pore size of the filter card
and absorbent matrix.
BRIEF DE$CRIPTIQN QF THE DRAWINGS
Fig. 1 is an exploded perspective view of the apparatus
of the invention.
Fig. 2 is a compilation of the results from Examples 1
and 2.
DETAILED DE$CRIPTIQN QF THE INVENTION
For ease in description, the method and apparatus of the
present invention will be explained with reference to the
separation and analysis of whole blood. However, the present
invention is not limited to whole blood. The invention also
may be used to separate and test other bodily fluids in situ,
whether of human or animal origin. Such bodily fluids
include, but are not limited to, blood, urine, saliva, tears,
menstrual fluid, ascitic fluid, peritoneal fluid, joint fluid,
cerebrospinal fluid, semen, transudate, or exudate. Knowing
the particular body fluid and the type of analyte to be
8
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tested, a person of skill in the art can determine the
appropriate parameters in light of the following description.
Referring to Fig. i, the apparatus I0 of the present
invention comprises tubing 12 or other means for transferring
5 a bodily fluid of interest into a collection chamber 14 formed
by an opening in a substantially flat or planar shell 16. The
shell 16, which is preferably made of a relatively inert clear
plastic, has flanges 20 at its outer edges which extend toward
a filter card 22. The surface area of the shell 16 adjacent
i0 to the filter card 22 is slightly larger than the surface area
of the filter card 22, so that, once the apparatus I0 is
assembled, the flanges 20 house the filter card 22
substantially abutting the opening in the shell 16. The sides
of the collection chamber 14 comprise the sides of the opening
15 in the shell 16 and the bottom of the chamber 14 comprises the
abutting filter card 22. The filter card 22 should be
positioned so that the blood or other bodily fluid that is
deposited in the collection chamber 14 covers substantially
the entire surface of the filter card 22 to infiltrate
20 substantially the entire filter card 22.
The filter card 22 may be composed of any suitable
fibrous material having a large surface area, an appropriate
density, and an appropriate average pore size. In a preferred
embodiment, the filter card 22 is made from glass fiber, which
MSC-22463-I Patent ApplicationU.S.Gov't
has a larger surface area than most fibers, permitting the use
of a smaller volume of fibrous material to separate the
components of the fluid. For whole blood, a desirable average
pore size is less than about 3 u, preferably about 1 u, and a
5 desirable density, if the filter card is made from glass
fiber, is a basis weigt of about 465 gm/m 2. Of course, the
density will change with the weight of the fibrous material;
however, lighter materials generally are preferred due to
their portability. A preferred embodiment uses #32 Glass
I0 Fiber Filter, Catalog # 08090, obtained from Schleicher and
Schuell (Keene, New Hampshire). Other suitable materials for
the filter card 22 include, but are not limited to, cellulose
fibers, natural organic fibers, semi synthetic fibers,
synthetic fibers, and hydrophilic polymeric gels.
15 The filter card 22 should be treated with a protein/
carbohydrate mixture comprised of between about 1-40% wt/vol
carbohydrate mixed with 0.1-15% wt/vol non-specific protein,
preferably about 10%-20% wt/vol carbohydrate and about 5-8-%
wt/vol protein. A preferred embodiment uses about 10% wt/vol
20 mannitol and about 6% wt/vol albumin.
Preferred carbohydrates include: monosaccharides, such
as fructose, galactose, and glucose; disaccharides, such as
mannitol, lactose, and sucrose; and, complex polymeric sugars,
such as starch and glycogen. Preferred proteins include human
i0
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plasma fractions, such as albumin, globulin, transport
proteins, and low molecular weight animal and vegetable
equivalents. The filter card 22 preferably is treated with
the protein/carbohydrate mixture by dipping the filter card 22
in a solution of the protein/carbohydrate solution and then
air drying the filter card 22.
Treatment of the filter card 22 with the
protein/carbohydrate mixture significantly improves the
efficiency of separation and permits the separation of
relatively large volumes of whole blood up to about 20
microliters. The amount of blood that can be separated is
limited only by the size of the apparatus i0. The relative
proportion, absolute amount, and composition of the
carbohydrate/protein mixture provides variable and optimal
control of the separation process while preventing cell lysis.
The speed, cleanliness, and efficiency of the separation
process can be altered by: (a) changing the absolute
concentration of carbohydrate and/or protein in the mixture;
(b) applying positive or negative pressure to one side of the
filter card 22; and/or (c) varying the relative size of pores
in the filter card 22 and absorbent matrix 30.
The "efficiency" of the process generally refers to the
ability of the process to extract the largest percentage of
available serum or acellular fluid contained in a particular
ii
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sample. The apparatus and method of the present invention
normally recovers approximately 80-100% of the serum in whole
blood. The "cleanliness" of the process refers to how
effectively the process screens the serum or fluid of cells
5 and/or other solids. Generally, increasing the concentration
of carbohydrate in the solution used to coat the filter card
22 increases the efficiency and cleanliness of the separation
but decreases the speed of the separation. Therefore, a
higher concentration of carbohydrate, in the range of 10-20%
i0 wt/vol, normally is preferred as long as the analytes to be
tested will survive for about 30 minutes to about 1 hour.
Some analytes are extremely delicate and/or have extremely
short half lives. In order to test for such analytes, it may
be necessary lower the concentration of carbohydrate somewhat
15 and accept a lower level of efficiency and cleanliness of the
process. In some cases, a preserving agent may be added to to
the sample before beginning the separation process in order to
preserve such analytes. Another way to preserve some short
lived analytes might be to include an antibody for the analyte
2O on the absorbent matrix 30.
specific antibody, itself,
further analysis.
After passing
The binding of the analyte to the
may preserve the analyte for
through the filter card 22, the plasma
fraction reaches an absorbent matrix 30 preferably positioned
12
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in direct contact with the filter card 22. The absorbent
matrix 30 should be made from a material having a relatively
high "Klemm" factor, on the order of at least about 15,
preferably about 30-70. The higher the Klemm factor, the more
5 passive force will be exerted on the sample to draw the sample
through the filter card 22. The Klemm factor should be as
high as possible without causing blood cells or other solid
matter to flow through the filter card 22. In a preferred
embodiment, the absorbent matrix 30 is Plasma Card Grade 900,
i0 a cellulose filter having a Klemm factor of about 64, obtained
from Schleicher & Schuell (Product #56630). Other suitable
materials for the absorbent matrix 30 include, but are not
limited to, sepharose gel, agar, and glass fiber matting.
Once assembled, the flanges 20 adhere to a back plate 24,
15 preferably forming a substantially water tight seal around the
filter card 22 and absorbent matrix 30 using any suitable
means known in the art. Although a substantially water tight
seal is preferred, the invention does not require a tightly
sealed filter in a pressure vessel, as do many other
20 techniques.
The tubing 12, or other means used to deposit the bodily
fluid in the collection chamber 14, may be directly connected
to a venous catheter or other access or collection port for
blood or another bodily fluid. In this way, the fluid sample
13
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can be immediately deposited in the collection chamber 14 and
analyzed substantially as it is collected. If the fluid is
blood, direct transfer of the fluid to the collection chamber
14 obviates the need for anticoagulation. If tubing is used,
5 the tubing 12 preferably is engaged with a plate 18 which has
a suitable adapter 26, such as a male Luer port. The transfer
of such fluid into the collection chamber 14 can be aided, if
desired, by aspiration with a syringe using an aspiration port
28 in the back plate 24. The aspiration port 28 may have any
i0 suitable construction which is compatible with an aspiration
syringe. For example, the port may be a female Luer port
which extends away from the body of the apparatus i0. The
aspiration port 28 preferably should be sealed using any known
means capable of maintaining the water tight seal within the
15 apparatus i0, but also permitting disruption of the seal if
aspiration is desired.
The separation process may be continued until the filter
card 22 and/or the absorbent matrix 30 is filled. The blood
or other bodily fluid is drawn by the high Klemm factor of the
20 absorbent matrix 30 and passes through the filter card 22 by
capillary action independent of gravity. The passive
operation of the apparatus I0 is advantageous because one of
the contemplated uses for the invention is to collect,
separate, and store blood or other bodily fluids during space
14
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flight in the absence of gravity. In addition, capillary
action does not require a centrifuge or other cumbersome
equipment to separate the bodily fluid. Compared to the glass
or plastic vials and powered equipment required to separate
5 bodily fluids by centrifuge, the apparatus i0 of the present
invention is extremely portable.
The absorbent matrix 30 preferably is supported in a
frame 32 made of any suitable material, preferably a
relatively inert clear plastic. The absorbent matrix 30 and
I0 the back plate 24 preferably are provided with pull-tabs 34.
When the filtration process is complete, the pull-tabs 34
permit the removal of the absorbent matrix 30 from the
apparatus i0 without the need for direct contact which could
contaminate the absorbent matrix 30.
15 The absorbent matrix 30 and/or the filter card 22 may be
impregnated with any number of suitable reagents to test for
particular analytes, including well known reagents used to
conduct specific antibody mediated assays, enzyme mediated
assays, ligand mediated assays, and binding resins. As
20 already alluded to, the filter card 22 and/or the absorbent
matrix 30 also may be impregnated with specific chemicals
and/or antibod(ies) which will preserve delicate or short
lived analytes for later extraction and analysis. Also,
because the separation process can begin substantially
15
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simultaneously with the collection of the bodily fluid,
biochemical changes in the concentration and/or structure of
analytes due to the presence of a cellular fraction are
minimized or eliminated. For example, the cellular fraction
5 is not available to consume glucose or other consumable
analytes in the sample. The preservation of short lived
and/or delicate analytes can be enhanced by prechilling the
apparatus I0 before use, and/or by transferring the apparatus
I0 to a cooled environment as soon as possible during or after
I0 the separation process.
The absorbent matrix 30 may be used and/or stored in a
number of different ways. In a preferred embodiment, the
absorbent matrix 30 is dried by subjecting the matrix to a
flow of dry air which preferably should not exceed body
15 temperature. Above about 40°C, enzymes and other delicate
analytes on the absorbent matrix 30 tend to degrade. Once
dried, the absorbent matrix can be placed in a container with
a desiccant and an oxygen scavenger, such as an activated
cuprous compound, to reduce the water content and oxygen
20 tension in the surrounding atmosphere. Preferably, the oxygen
content of the air surrounding the sample should be maintained
as close as possible to 0%. The sample also preferably should
be isolated from light. Otherwise, the sample may be stored
in ambient conditions. The addition of standard anti-
16
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peptidase chemicals, antioxidants, and/or preservatives will
protect certain analytes whose concentrations may be altered
in the drying process. Compared to other available methods
for storing such samples, the procedures required to preserve
5 and store the absorbing matrix 30 in robust condition are
simple, inexpensive, and portable.
Storing bodily fluids on the absorbent matrix 30 can
preserve a broad range of the analytes for clinical and
research purposes for extended periods of at least days to
I0 weeks. In fact, some analytes which are very difficult to
preserve by freezing have been preserved using the present
invention.
The use of a clear plastic shell 16, flanges 20, and back
plate 24 will result in an additional advantage. The clear
15 plastic will permit the filtration process to be observed. An
end point for the process can be selected by choosing an
acceptable time, determined partly by the design of the filter
and the fluid being absorbed or by watching the area of
discoloration of the absorbing matrix 30 through the back
20 plate 24. Furthermore, the chemical testing reagent(s) can be
impregnated onto either the absorbent matrix 30 or both the
absorbent matrix 30 and/or the filter card 22 and then a color
change, agglutination, or other process taking place on the
absorbing matrix 30 can be observed through the clear plastic.
17
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In addition, the assay may be by direct fluoroscopy,
spectroscopy, or thermal or electrical impedance. The latter
will require the incorporation of appropriate electrodes into
the plastic back plate.
5 The apparatus i0 also can be adapted so that the results
can be quantified. For example, a line of reagent "dots" may
be engineered into the apparatus i0 so that the dots react to
a specific concentration of analyte. After reaction, the dots
may be compared to a scale which will quantify the results of
i0 such reaction. For example, the dots could be engineered to
change color either absolutely or to an intensity that relates
to the concentration of a particular analyte in the sample.
The color of the dots after the reaction could be used to
extrapolate the concentration of the analyte present in the
15 whole blood, e.g., by comparison to a color scale which may
be separate from or incorporated into the apparatus.
If a series of dots is used, the reagent dots may be a
specific chemical, such as a dye which changes color with pH
or with the progress of an enzymatic process or cascade. For
20 example, such a dot could be capable of detecting glucose
through the action of the enzyme glucose oxidase. In a
preferred embodiment, the "dot" detects an antibody mediated
reaction which is specific to an analyte or a group of
analytes. The antibody specifically binds to the analyte in
18
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the absorbing matrix and initiates a cascade of immunochemical
reactions which produce an observable change.
In another preferred embodiment of the device, the
antibody may be loosely bound in the filter card 22, itself,
5 and therefore may pass through only with the passage of an
analyte. Or, the antibody may be free in the filter card 22
or the collection chamber 14 such that the antibody is bound
to a cell and does not pass through into the absorbent matrix
30 to initiate an identifying cascade. Any number of
i0 variations may be made to adapt test reagents for use in the
present invention.
The invention will be more clearly understood with
reference to the following examples.
Ex_mpl_ 1
15 In this experiment (Protocol i), blood was collected from
a crewmember on the Space Shuttle into both a vacutainer and
into the dried-blood collection device of the present
invention. After insertion of an appropriate venous cannula
or butterfly using standard procedures, the vacutainer adapter
20 was attached and two 5 ml samples of whole blood were
collected into two 5 ml vacutainer tubes. The venous line was
occluded and the vacutainer adapter removed.
A blood collection device was attached to the cannula and
inspected visually while it was filling. The operator was
19
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able to look through the clear casing of the blood collection
device and observe the filling of the chamber with blood.
After the chamber filled completely, the venous line again was
occluded. The process was
collection devices were filled.
or removed.
repeated until five blood-
The cannula then was sealed
The collection devices were fitted with velcro tabs to
anchor them to the working area and set aside for about one
hour. After completion of the blood collection, the blood
i0 collection devices were inspected, and any droplets floating
free in the chamber behind the paper filter noted. If free
fluid was present, the blood-collection device was moved to
the drop until the drop was absorbed onto the absorbent
material. When no free droplets were visible, the blood
15 collection device was opened and the paper filter containing
the plasma was removed by pulling the tab. The casing of the
blood-collection device was closed and the entire unit was
discarded. The storage card then was transferred into the
drying box where it slid down into grooves that supported and
20 spaced the cards. The process was repeated for all 5 cards.
A fan in the drying box was turned on and the cards were dried
in a flow of room air for about 2 hours. At the end of the 2
hours, the fan was turned off and the dessicant and oxygen
scavenger was activated by removing the protective cover for
2O
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these materials. The lid of the drying box was then closed
and the cards were left in the box for storage.
The two vacutainer samples were placed in a centrifuge
and cells and plasma were separated according to established
5 procedure. The vacutainers then were placed in approximately
-20°C refrigeration and the time and date recorded. The
entire unit was stowed for the remainder of the mission.
After landing, the frozen serum was removed within 8
hours and transferred to a refrigerated transfer canister.
i0 The dried cards in stowage also were retrieved and all samples
returned for postflight analysis. Two days after landing, the
serum was thawed, the dried cards were rehydrated, and the
serum was extracted. The rehydration process involved
removing the paper filter from its plastic support frame,
15 folding the filter, placing the filter inside a i0 ml tube,
adding a set quantity of distilled water, rotating the tubes
for 5 minutes and then extracting serum from the moistened
paper by compressing the paper with the plunger of the syringe
and emptying the sample into the glass tube.
20 The two sets of serum were analyzed simultaneously for
the molecules shown in Fig. 2. The majority of analytes were
measured in an automated CX 5 biochemistry unit obtained from
Beckman Instruments (Brea, CA) using a combination of
amperometric and photometric methods. Most of the hormones
21
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are analyzed by radioimmunoassay using commercially available
methods.
During the in-flight phase of the study, a ground-based
control was run in which blood was drawn from two individuals
5 using the same protocol and stored frozen or dried onto the
filter paper in the same way. The ground-based samples were
subjected to conditions that were as similar to those of the
in-flight samples as practical and were thawed or extracted
and analyzed at the same time.
i0 Data from the in-flight samples and ground-based controls
were analyzed for mean, standard deviation, and coefficient of
variation. Results from in-flight samples stored frozen were
compared to results from the dried stored samples. The
results are shown in Fig. 2.
15 The dried-blood-chemistry method provided accurate
correlation to frozen samples taken in flight. In addition,
the dried blood chemistry results show, in ground-based
studies, a high correlation with samples of the same serum
tested fresh.
22
MSC-22463-I Patent ApplicationU.S. Gov]
ExamDle 2
Serum for this experiment (Protocol 2) was collected and
pooled. Known quantities of certain analytes were added to
artificially increase the concentrations to allow for some
5 degradation before the experiment was begun and to give a
broad representative group of all of the subcomponents of
serum. The pooled serum with "spiked" concentrations of
certain molecules, including melatonin, angiotensin, anti-
diuretic hormone, and atrial naturetic factor, was filter
i0 sterilized, and loaded into 17 syringes two days before
launch. Thirteen of the syringes contained the exact volume
known to be held by the cards from ground-based studies, one
contained about 3 mls of the correct volume, and five
contained about 7 mls of the known volume. The remaining two
15 5 ml syringes served as controls, and were stored frozen after
the fluid had been placed on the cards.
Each syringe was capped and wrapped in Teflon tape to
prevent leakage if broken. Each syringe was labeled with a
code number and had a matching storage card similarly labeled.
20 The syringes and cards were stored inside a semirigid "NOMEX"
(thick cloth) bag inside of a -20°C freezer. A drying box
identical to the box used in the first experiment also was
flown.
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On a flight day early to midway through the mission, the
syringes and cards were removed from their protective bags and
each syringe was emptied in sequence onto its paired storage
card. The emptied syringes were discarded. The two remaining
syringes were stored frozen and the time and date were
recorded. The cards were transferred to the "drying box" and
the drying box fan turned on for about 2 hours. At the end of
this period, the "rip-top" desiccant and oxygen scavenger
container were opened and the drying box closed. The entire
drying box, with cards inside, were placed inside a second
plastic bag. The bag was sealed, and the entire unit was
stowed in a middeck locker for the duration of the mission.
After landing, the samples were handled as described in
Example i.
The dried-blood-chemistry method provided accurate
correlation to frozen samples taken in-flight. In addition,
the dried blood chemistry results showed, in ground-based
studies, a high correlation with samples of the same serum
tested fresh.
The invention has been described in connection with a
particular embodiment. One of skill in the art will
appreciate that many modifications may be made to the
embodiment described herein without departing from the spirit
of the present invention. Accordingly, the embodiment
24
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described herein is illustrative only and is not intended to
limit the scope of the present invention.
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ABSTRACT OF THE INVENTION
The present invention provides a simple, portable,
relatively inexpensive apparatus for accurately and
efficiently collecting, separating, testing, and even storing
5 between about 1-20 ml, preferably about i-i0 ml, of blood or
other bodily fluid in situ. The apparatus includes a
collection chamber bounded on its sides by an opening in a
sheet of material, preferably clear plastic, abutting a filter
card. The filter card is made of fibrous material,
i0 prefereably less than about a millimeter thick, having an
average pore size of less than about 3 microns. Preferably,
the fibers are glass and the fibrous material has an average
pore size of about 1 micron. The fibrous material is treated
with a carbohydrate/protein mixture which contains between
15 about 1-40% wt/vol carbohydrate and about 0.1-15% wt/vol non-
specific protein, preferably between about 10-20% carbohydrate
and about 5-8% protein. A preferred carbohydrate/protein
mixture comprises about 10% mannitol and about 6% albumin.
The blood or other fluid moves through the filter card by
20 capillary action aided by an absorbent matrix with a high
Klemm factor which abuts the filter card. The absorbent
matrix and/or filter card can be treated with a wide spectrum
of test reagents. The speed, cleanliness, and efficiency of
the separation process can be altered by: (a) changing the
MSC-22463-I Patent Application
U.S. Gov t
absolute concentration of the carbohydrate/protein mixture;
(b) applying positive or negative pressure to one side of the
filter; and/or (c) varying the relative density and pore size
of the filter card and absorbent matrix.
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FIGURE 2
Electrolytes
R*
Sodium R
Chloride R
Potassium R
Calcium R
Magnesium L**
Phosphate
Metabolites
R
Glucose R
Urea R
Cholesterol L
Uric acid
Tri glyceride R
Total protein R
Total Bilirubin R
R
Creatinine
Blood urea nitrogen R
Aspartate Transaminase L
Alkaline Phosphatase R
Alanine transaminase L
Gamma glutaryl transferase R
L
Amylase L
Lactate dehydrogenase L
Creatinine kinase
Hormones and related enzymes
Protocol
I & 2
i & 2
i & 2
i & 2
I & 2
i & 2
i &2
1 &2
i & 2
I & 2
2
i & 2
i & 2
1 & 2
I &2
1 &2
i & 2
i &2
I & 2
i & 2
i & 2
1 & 2
R I
Thyroxine R 2
Insulin R I & 2
Cortisol R 2
Atrial naturetic factor R I & 2
Angiotensin R 2
Melatonin
*"R" Recovered fully.
**"L" recovered but at a lower level than frozen serum.
